Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Francisco Quintana
Brigham and Women's Hospital, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
AnTolRx, Inc.
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
The research projects will study the molecular pathways regulating T-cell response in autoimmune diseases, particularly multiple sclerosis (MS). The research will focus on the role of AHR/CD39 and eATP/HIF1α in control of Tr1 cells. The company, AnTolRx, Inc., uses AHR to induce immune tolerance and has an MS treatment in its development pipeline. Understanding the regulation of the autoimmune T-cell response and its potential as a therapeutic target could affect the financial interests of a company working on AHR in MS. Given the investigator’s private equity interest and cash compensation, it was determined that the interest could affect the design, conduct, or reporting of the research projects, resulting in a financial conflict of interest under the PHS regulations.
Regulation of CNS Autoimmunity
PROJECT NARRATIVE Autoimmune diseases like multiple sclerosis are caused by the uncontrolled activity of the immune system. This project proposes to use mouse and human systems to study novel molecular pathways that control the immune response and to identify potential targets for therapeutic immune modulation.
Filed on March 24, 2017.
Tell us what you know about Francisco Quintana's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Francisco Quintana filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Francisco Quintana | Brigham and Women's Hospital | Conflict of Interest | AnTolRx, Inc. | $40,000 - $59,999 |
| Francisco Quintana | Brigham and Women's Hospital | Conflict of Interest | AnTolRx, Inc. | $40,000 - $59,999 |
| Francisco Quintana | Brigham and Women's Hospital | Conflict of Interest | AnTolRx, Inc. | Value cannot be readily determined |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.